US FDA grants EUA for TRUPCR® SARS CoV-2 V.2 RT gPCR Kits

KILPEST India Ltd. (BSE: KILPEST I 532067 I INE994E01018) with its subsidiary 3B Blackbio Biotech India Ltd., the fastest growing Indian molecular Diagnostics company, today announced that the U.S. Food and Drug Administration (FDA) has granted emergency use authorization (EUA) for its multiplex real-time PCR test intended for the qualitative detection of nucleic acid from SARS-CoV-2, the virus that causes COVID-19.

With this, 3B Blackbio Biotech India Ltd. becomes first ever Indian molecular diagnostics company to receive US FDA-(EUA). Especially at times when more and more reliable testing is the need of the hour for India as well as other countries, TRUPCR® will be reliable options for labs across the globe to perform the molecular testing for Covid-19 suspected individuals.

TRUPCR® SARS CoV-2 V.2 RT qPCR Kits with its unique design of screening and confirmatory assays which detects three genes from the SARS-CoV-2 virus with Endogenous Control gene (RNase P) Internal control for each sample to minimize false negative results.

With Grant of US FDA-(EUA), we would be able to expand our customer base globally, and we would emerge as one of the most reliable RT qPCR Kits suppliers from India. Ensuring success to "MAKE IN INDIA" vision of Hon'ble P.M.

Shares of KILPEST INDIA LTD. was last trading in BSE at Rs.168.45 as compared to the previous close of Rs. 170.4. The total number of shares traded during the day was 31638 in over 428 trades.

The stock hit an intraday high of Rs. 174.9 and intraday low of 166.4. The net turnover during the day was Rs. 5362080.

Source : Equity Bulls

Keywords